Drugs / SB26
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03630627 | Aug 2018 → Apr 2020 | — | Samsung Bioepis Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-08-13 | Samsung Bioepis Co., Ltd. | Regulatory 삼성바이오에피스, 급성 췌장염 신약 개발 시동 samsungbioepis.com ↗
삼성바이오에피스는 미국 식품의약국(FDA)에 제출한 임상 1상 시험 신청서(IND:Investigational New Drug Application)를 승인받았으며, 추후 참가자 등록을 통해 단회 및 반복 투여 임상시험을 진행할 계획이다. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-08-13 | Samsung Bioepis Co., Ltd. | 삼성바이오에피스, 급성 췌장염 신약 개발 시동 samsungbioepis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB26 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03630627 ↗ |
| Route | Intravenous | “SB26 administered intravenously” NCT03630627 ↗ |